X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs MERCK LTD - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES MERCK LTD PIRAMAL ENTERPRISES/
MERCK LTD
 
P/E (TTM) x 9.6 46.6 20.7% View Chart
P/BV x 1.7 7.0 23.6% View Chart
Dividend Yield % 1.0 0.4 244.7%  

Financials

 PIRAMAL ENTERPRISES   MERCK LTD
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-18
MERCK LTD
Dec-16
PIRAMAL ENTERPRISES/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs3,0831,060 290.9%   
Low Rs1,902623 305.3%   
Sales per share (Unadj.) Rs589.7632.4 93.2%  
Earnings per share (Unadj.) Rs284.045.7 621.3%  
Cash flow per share (Unadj.) Rs310.562.3 498.3%  
Dividends per share (Unadj.) Rs25.0011.00 227.3%  
Dividend yield (eoy) %1.01.3 76.7%  
Book value per share (Unadj.) Rs1,467.0388.8 377.3%  
Shares outstanding (eoy) m180.2716.60 1,086.0%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x4.21.3 317.6%   
Avg P/E ratio x8.818.4 47.7%  
P/CF ratio (eoy) x8.013.5 59.4%  
Price / Book Value ratio x1.72.2 78.5%  
Dividend payout %8.824.1 36.6%   
Avg Mkt Cap Rs m449,33213,969 3,216.7%   
No. of employees `0006.81.6 432.3%   
Total wages/salary Rs m19,8811,487 1,337.3%   
Avg. sales/employee Rs Th15,535.66,631.9 234.3%   
Avg. wages/employee Rs Th2,905.4939.2 309.4%   
Avg. net profit/employee Rs Th7,482.5479.4 1,560.8%   
INCOME DATA
Net Sales Rs m106,31010,498 1,012.6%  
Other income Rs m2,595242 1,070.7%   
Total revenues Rs m108,90610,741 1,014.0%   
Gross profit Rs m51,5991,135 4,544.9%  
Depreciation Rs m4,773276 1,732.6%   
Interest Rs m29,7830-   
Profit before tax Rs m19,6381,102 1,781.7%   
Minority Interest Rs m2,8010-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-28,764343 -8,378.7%   
Profit after tax Rs m51,203759 6,747.0%  
Gross profit margin %48.510.8 448.8%  
Effective tax rate %-146.531.1 -470.3%   
Net profit margin %48.27.2 666.3%  
BALANCE SHEET DATA
Current assets Rs m118,1546,410 1,843.4%   
Current liabilities Rs m462,2608,828 5,236.1%   
Net working cap to sales %-323.7-23.0 1,404.9%  
Current ratio x0.30.7 35.2%  
Inventory Days Days2758 46.1%  
Debtors Days Days4738 121.2%  
Net fixed assets Rs m113,7271,406 8,086.4%   
Share capital Rs m361166 217.2%   
"Free" reserves Rs m264,0936,286 4,201.3%   
Net worth Rs m264,4546,455 4,097.1%   
Long term debt Rs m242,2060-   
Total assets Rs m726,8348,828 8,233.0%  
Interest coverage x1.7NM-  
Debt to equity ratio x0.90-  
Sales to assets ratio x0.11.2 12.3%   
Return on assets %11.18.6 129.6%  
Return on equity %19.411.8 164.7%  
Return on capital %10.317.1 60.4%  
Exports to sales %08.3 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs mNA2,209 0.0%   
Fx inflow Rs m15,110959 1,575.9%   
Fx outflow Rs m4,2982,612 164.5%   
Net fx Rs m10,813-1,653 -654.0%   
CASH FLOW
From Operations Rs m-159,6661,070 -14,916.5%  
From Investments Rs m-17,677-750 2,357.9%  
From Financial Activity Rs m186,503-150 -124,501.0%  
Net Cashflow Rs m9,364171 5,479.4%  

Share Holding

Indian Promoters % 52.9 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 4.0 18.2 22.0%  
FIIs % 26.6 1.0 2,660.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 29.1 56.7%  
Shareholders   93,274 28,591 326.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  ABBOTT INDIA  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open Flat; Pharma Stocks Gain(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.5% while the Hang Seng is up 1%.

Related Views on News

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Sep 26, 2018 10:53 AM

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES - TTK HEALTHCARE COMPARISON

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS